• CEO: Marguerite Mensonides
• Chairman of the board: Rob Mayfield

Amplio Pharma is a rare opportunity to invest in a de-risked, patent-protected asset with the potential to redefine first-line rheumatoid arthritis treatment. NovoBioJect builds on methotrexate, the established global standard, and has already generated human biomarker data supporting superior efficacy. Rather than competing in crowded biologics markets, it aims to replace the current first-line therapy, creating access to a multi-billion-dollar market opportunity. With Phase IIa ahead, €10 million of Series A financing, and a defined acquisition pathway by major immunology players, Amplio offers investors a realistic near-term exit opportunity and the potential for outsized returns.

• CEO: Michael Malkoch
• Chairman of the board: Michael Malkoch

Every second, more than five people somewhere in the world break a bone. Most of us will break at least two in a lifetime. Fracture is not a niche indication. It is one of the few medical events almost every human being will experience.Yet the repair has barely changed in seventy years. A rigid metal plate is manufactured long before the injury exists, chosen from a catalogue of sizes and bent by hand to approximate a bone it was never made for. The compromise is sharpest where the need is greatest. In osteoporotic bone, screws lose their purchase, and a plate many times stiffer than the bone it supports shields that bone from load and concentrates stress at its ends, where the next fracture begins.

Biomedical Bonding AB is a Swedish MedTech company founded to remove that compromise. Bonevolent®, a patented light-cured composite platform spun out of KTH Royal Institute of Technology in Stockholm and grounded in more than a decade of research and peer-reviewed biomechanical evidence, allows the surgeon to build a load-bearing fixator directly on the bone and cure it on demand. The implant is shaped to the fracture rather than the fracture to the implant, and it cures to a stiffness close to bone itself.The human skeleton has 206 bones, and almost every one of them can break in a way that a fixator shaped in theatre fits better than anything made in advance. That is the scale BMB is building towards: veterinary market entry in 2027, the first human fracture fixed in 2028, followed by market launch in 2030.

• CEO: Martin Welschof
• Chairman of the board: Leonard Kruimer

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of solid tumors and hematological cancer. Its validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

• CEO: Hilde H. Steineger
• Chairman of the board: Magnus Persson

Cantargia is a clinical-stage biotech company developing antibody therapies targeting IL1RAP, a key driver in cancer and inflammatory diseases. Our lead asset, nadunolimab, shows promising clinical activity in hard‑to‑treat cancers such as pancreatic cancer, addressing a major unmet medical need. In parallel, CAN10 creates significant value through a global partnership with Otsuka, including milestone payments and royalties. With a differentiated mechanism, advancing clinical programs, and strong partnering potential, Cantargia offers a compelling opportunity in high‑impact therapeutic areas.

• CEO: Petter Segelman Lindqvist
• Chairman of the board: Jan-Eric Österlund

Isofol is a clinical-stage biotechnology company dedicated to improving outcomes for patients with difficult-to-treat cancers. The company’s drug candidate, arfolitixorin, is a next-generation folate therapy designed to enhance the efficacy of established standard treatments for solid tumors. Arfolitixorin is initially and currently being evaluated in a Phase Ib/II clinical trial in metastatic colorectal cancer, the second leading cause of cancer-related death worldwide and an area of significant unmet medical need. Isofol is listed on Nasdaq Stockholm.

• CEO: Ulrika Warpman Berglund
• Chairman of the board: Eva Sjökvist Saers

Oxcia AB is a clinical-stage biotech company pioneering therapies that target key drivers of many diseases, using its proprietary O2-DDR platform (Oxidative stress, Oxidative DNA damage, and DNA Damage Response (DDR)). The platform has so far generated two first-in-class drug candidates: OXC-101, currently in clinical development for acute myeloid leukemia with both FDA and EMA Orphan Drug Designations, and OXC-201, a novel treatment for idiopathic pulmonary fibrosis supported by European Innovation Council funding. By addressing major unmet medical needs through a differentiated scientific approach, Oxcia aims to deliver transformative therapies to make life less short, creating significant value for patients and investors.

• CEO: Nina E Beer
• Chairman of the board: Johan Ryden

redhot Diagnostics commercializes standardized kits for LC-MS/MS, the gold-standard method in clinical chemistry. Most laboratories still run these tests on in-house protocols, so results vary from one laboratory to the next, and IVDR is steadily closing that route. redhot replaces the protocols with validated, CE-marked kits.The lead product measures PEth, a substance formed only in the presence of alcohol, giving it 100 percent biochemical specificity and a detection window of several weeks. It is used in addiction medicine, liver and transplant clinics, and clinical trials. The kit is on the market today, generating recurring revenue at gross margins above 90 percent with almost no commercial effort behind it.Kits for drug monitoring and vitamin B12 deficiency are in development, alongside rhelise™, a patented home-sampling kit that keeps a blood sample stable for more than two weeks at room temperature. A further application filed in 2026 covers improved calibrators and controls.redhot diagnostics is raising capital to expand European and US distribution and build a multi-marker LC-MS/MS platform.